BridgeBio Pharma BBIO Total debt

Total debt at other companies

PfizerPFE

$64.43B+4.9%

Ionis PharmaceuticalsIONS

$262.48M-67.0%

BioMarin PharmaceuticalsBMRN

$4.19B+598%

ALN

Alnylam PharmaceuticalsALNY

$256.43M-5.2%

CelcuityCELC

$137.89M+30.7%

Revolution Medicines, Inc.RVMD

$154.49M+16.3%

FAQ

What is BridgeBio Pharma's total debt?

BridgeBio Pharma (BBIO) reported total debt of $3.26B in Q1 2026.

How has BridgeBio Pharma's total debt changed year-over-year?

BridgeBio Pharma's total debt increased by 32101.0% year-over-year, from $10.12M to $3.26B.

What is the long-term trend for BridgeBio Pharma's total debt?

Over 5 years (2020 to 2025), BridgeBio Pharma's total debt has grown at a -38.5% compound annual growth rate (CAGR), from $114.05M to $10M.

What does total debt mean?

Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.